Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
Spevatamig is Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I₂E), an emerging class of immuno-oncology (IO) agents. Spevatamig is currently in Phase 2 studies for the treatment of multiple forms of gastrointestinal cancers. The expansion of...
Spevatamig is Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I₂E), an emerging class of immuno-oncology (IO) agents. Spevatamig is currently in Phase 2 studies for the treatment of multiple forms of gastrointestinal cancers. The expansion of...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.